BACKGROUND AND OBJECTIVE: Fibroblast growth factor 23 (FGF-23), a regulator of phosphorus metabolism, is a risk marker in CKD. FGF-23 has been associated with coronary arterial calcification (CAC), but it is not known whether FGF-23 predicts CAC progression in CKD. The aim of this study was to evaluate the association of FGF-23 with CAC progression in advanced CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: FGF-23 levels and CAC were measured by electrocardiography-triggered multislice computed tomography in 99 individuals initiating dialysis. Patients were enrolled in the study from April 2008 to July 2010. CAC was calculated using Agatston and calcium volume score. Sixty-seven study participants had repeat CAC measures at 1 year. Linear regression was used to assess the association of FGF-23 with CAC. RESULTS: The mean age of study participants was 50 years; 33% were women, and 64% were black. The median FGF-23 level was 1238 relative units (RU)/ml (interquartile range, 515-2218 RU/ml). According to Agatston score, FGF-23 was not associated with baseline CAC (P=0.14) but was significantly associated with CAC progression. There was a 192.3-Agatston unit change in CAC score per 1-SD change in FGF-23 (P=0.008) in models adjusting for known risk factors for CAC and serum phosphate. This association persisted after adjustment for high-sensitivity C-reactive protein, 25-OH vitamin D levels, and the use of phosphorus binders. Results were similar when change in calcium volume score was used. CONCLUSIONS: In individuals with advanced CKD, serum FGF-23 is strongly associated with CAC progression. FGF-23 may be a marker of cardiovascular risk in CKD.
BACKGROUND AND OBJECTIVE:Fibroblast growth factor 23 (FGF-23), a regulator of phosphorus metabolism, is a risk marker in CKD. FGF-23 has been associated with coronary arterial calcification (CAC), but it is not known whether FGF-23 predicts CAC progression in CKD. The aim of this study was to evaluate the association of FGF-23 with CAC progression in advanced CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: FGF-23 levels and CAC were measured by electrocardiography-triggered multislice computed tomography in 99 individuals initiating dialysis. Patients were enrolled in the study from April 2008 to July 2010. CAC was calculated using Agatston and calcium volume score. Sixty-seven study participants had repeat CAC measures at 1 year. Linear regression was used to assess the association of FGF-23 with CAC. RESULTS: The mean age of study participants was 50 years; 33% were women, and 64% were black. The median FGF-23 level was 1238 relative units (RU)/ml (interquartile range, 515-2218 RU/ml). According to Agatston score, FGF-23 was not associated with baseline CAC (P=0.14) but was significantly associated with CAC progression. There was a 192.3-Agatston unit change in CAC score per 1-SD change in FGF-23 (P=0.008) in models adjusting for known risk factors for CAC and serum phosphate. This association persisted after adjustment for high-sensitivity C-reactive protein, 25-OH vitamin D levels, and the use of phosphorus binders. Results were similar when change in calcium volume score was used. CONCLUSIONS: In individuals with advanced CKD, serum FGF-23 is strongly associated with CAC progression. FGF-23 may be a marker of cardiovascular risk in CKD.
Authors: John E Hokanson; Todd MacKenzie; Gregory Kinney; Janet K Snell-Bergeon; Dana Dabelea; James Ehrlich; Robert H Eckel; Marian Rewers Journal: AJR Am J Roentgenol Date: 2004-05 Impact factor: 3.959
Authors: Ravi Dhingra; Lisa M Sullivan; Caroline S Fox; Thomas J Wang; Ralph B D'Agostino; J Michael Gaziano; Ramachandran S Vasan Journal: Arch Intern Med Date: 2007-05-14
Authors: Hartmut H Malluche; Gustav Blomquist; Marie-Claude Monier-Faugere; Thomas L Cantor; Daniel L Davenport Journal: J Am Soc Nephrol Date: 2015-04-02 Impact factor: 10.121
Authors: Mehmet Nuri Turan; Fatih Kircelli; Mustafa Yaprak; Ali Riza Sisman; Ozkan Gungor; Selen Bayraktaroglu; Mehmet Ozkahya; Gulay Asci; Jurgen Floege; Ercan Ok Journal: Int Urol Nephrol Date: 2016-02-10 Impact factor: 2.370
Authors: Pablo Molina; Mariola D Molina; Luis M Pallardó; Javier Torralba; Verónica Escudero; Luis Álvarez; Ana Peris; Pilar Sánchez-Pérez; Miguel González-Rico; María J Puchades; José E Fernández-Nájera; Elena Giménez-Civera; Luis D'Marco; Juan J Carrero; José L Górriz Journal: J Nephrol Date: 2021-01-04 Impact factor: 3.902
Authors: Pranav S Garimella; Joachim H Ix; Ronit Katz; Michel B Chonchol; Bryan R Kestenbaum; Ian H de Boer; David S Siscovick; Shani Shastri; Jade S Hiramoto; Michael G Shlipak; Mark J Sarnak Journal: Atherosclerosis Date: 2014-01-04 Impact factor: 5.162
Authors: Joshua D Bundy; Jing Chen; Wei Yang; Matthew Budoff; Alan S Go; Juan E Grunwald; Radhakrishna R Kallem; Wendy S Post; Muredach P Reilly; Ana C Ricardo; Sylvia E Rosas; Xiaoming Zhang; Jiang He Journal: Atherosclerosis Date: 2018-02-10 Impact factor: 5.162
Authors: Poyyapakkam R Srivaths; Stuart L Goldstein; Rajesh Krishnamurthy; Douglas M Silverstein Journal: Pediatr Nephrol Date: 2013-08-08 Impact factor: 3.714